Literature DB >> 1535088

Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.

H Rabinowich1, D Vitolo, S Altarac, R B Herberman, T L Whiteside.   

Abstract

Peritumoral injection of human IL-2-activated natural killer cells into nude mice consistently induced regression of xenografts of human squamous cell carcinoma of the head and neck (SCCHN). To determine the mechanisms responsible for the tumor regression, the lymphoid cells infiltrating the tumor stroma at 24 to 48 h after adoptive immunotherapy were examined by in situ hybridization for the presence of mRNA for cytokines or IL-2R. Numerous lymphoid cells expressing cytokine or IL-2R genes were observed in these tumors, whereas the cultured IL-2-activated NK cells used for therapy were negative. Thus, it appeared that the transferred NK cells became activated in situ after coming into proximity with the tumor cells. To analyze this phenomenon, fresh or cultured human NK cells were coincubated in vitro with irradiated human SCCHN cell line, PCI-1, with or without the presence of IL-2. Expression of mRNA for IL-2R, perforin, and various cytokines was observed within 5 h. Contact with the tumor cells stimulated NK cells to proliferate, secrete IFN-gamma, TNF-alpha, and soluble IL-2R, up-regulate cell surface expression of IL2R p55 and p75 as well as CD16 Ag, and mediate higher levels of antitumor activity in 51Cr-release assays. In addition, supernatants of in vitro-activated NK cells significantly inhibited proliferation of SCCHN cell lines. By examining the effects of neutralizing mAb to various cytokines, this inhibitory activity was shown to be partially attributable to IFN-gamma. To determine the possible in vivo role of soluble factors produced by activated human NK cells, the supernatants (0.2 ml) or rIFN-gamma (10(5) U) were injected perilesionally each day for 2 wk into 3-day SCCHN established in immunosuppressed nude mice. These treatments caused significant (p less than 0.02) inhibition of tumor growth. The results of our studies indicate that human NK cells are strongly activated by SCCHN cells and that the consequent release of cytokines contribute to the regression of SCCHN growing in nude mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535088

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

Review 2.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

3.  MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: preclinical studies in a rodent model.

Authors:  Alexander Y Sheu; Zhuoli Zhang; Reed A Omary; Andrew C Larson
Journal:  Invest Radiol       Date:  2013-06       Impact factor: 6.016

4.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Authors:  W J Murphy; T C Back; K C Conlon; K L Komschlies; J R Ortaldo; T J Sayers; R H Wiltrout; D L Longo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 5.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck.

Authors:  P G Sacks
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

6.  (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

Authors:  David Loose; Alberto Signore; Ludovicus Staelens; Katia Vanden Bulcke; Hubert Vermeersch; Rudi Andre Dierckx; Elena Bonanno; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

Review 7.  Interferons and other cytokines in head and neck cancer.

Authors:  V K Hamasaki; E E Vokes
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

8.  Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias.

Authors:  I Munno; M Marinaro; A Gesario; B Cannuscio; Y Michel; E Paulling
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

9.  Immune parameters of mice bearing human head and neck cancer.

Authors:  A Taitz; G Petruzzelli; A S Pak; M A Wright; J P Matthews; W F Raslan; Y Lozano; M R Young
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Cytokine production and expression of adhesion molecules and integrins in tumor infiltrating lymphomononuclear cells of non-small cell carcinomas of the lung.

Authors:  D Vitolo; M B Palmieri; L P Ruco; E Rendina; G Bonsignore; C D Baroni
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.